EBM in action: "Does ovulation induction increase the risk of ovarian cancer?"

Middle East Fertility Society Journal

Volumn 11, Issue 2, 2006, Pages 135-139

  Attia, Abdelhamid ^a,b,c  

^a CAIRO UNIVERSITY   (Egypt)

^b Arab Federation of Evidence Based Medicine   (Egypt)

^c NONE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; FERTILITY PROMOTING AGENT; HUMAN MENOPAUSAL GONADOTROPIN; UROFOLLITROPIN;

ANOVULATION; CANCER RISK; EVIDENCE BASED MEDICINE; FEMALE INFERTILITY; HUMAN; OVARY CANCER; OVULATION INDUCTION; REVIEW;

EID: 33751230792     PISSN: 11105690     EISSN: 11105690     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Whittemore AS, Harris R, Itnyre J, and the Collaborative Cancer Group. Characteristics relating to ovarian cancer risk - collaborative analysis of 12 US case-control studies II: invasive epithelial cancers in white women. Am J Epidemiol 1992;136:1184-1203
2. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2.
3. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol. 2004;103:1194-1203
4. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V. Users' guides to the medical literature. IV. How to use an article about harm. Evidence-Based Medicine Working Group. JAMA. 1994;271:1615-1619
5. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? [letter]. Lancet 1971;2:163